Companion Diagnostics Market

Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022

Report Code: MD 5463 Aug, 2017, by marketsandmarkets.com

[170 Pages Report] The global companion diagnostics market is expected to reach USD 6.51 billion by 2022 from USD 2.17 billion in 2016, at a CAGR of 20.1%.

A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain diseases could be benefitted by a particular drug through the biomarker assessment. The key factors driving the growth of this market include the increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the companion diagnostics market. The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022.

Market Dynamics

Drivers

  • Improvements in regulatory guidelines
  • Growing need for targeted therapies
  • Rising cancer incidence worldwide
  • Increasing collaborations and partnerships for companion diagnostics test development

Restraint

  • Uncertain reimbursement scenarios in different regions

Opportunities

  • Increasing demand for next-generation sequencing (NGS)
  • Increasing number of clinical trials to boost the adoption of companion diagnostics
  • Emerging applications of companion diagnostics in other cancer indications, neurological disorders, infectious diseases, and cardiovascular diseases

Challenges

  • Intellectual property rights protection issues

Increasing collaborations and partnerships for companion diagnostics test development

Owing to the advantages of companion diagnostics in drug approval processes, an increasing number of pharmaceutical companies have entered into partnerships and collaborations with different companion diagnostic companies to develop and commercialize companion diagnostics tests for their drugs. For instance, in 2016, Agilent Technologies, Inc. and Applied Spectral Imaging (ASI) entered into a marketing agreement. ASI's most advanced GenASIs imaging platforms and Agilent's fluorescence in situ hybridization (FISH) products and solutions will be marketed by them. Simalarly in 2016, QIAGEN collaborated with Array BioPharma to develop and commercialize a companion diagnostic test. The test will be developed for Array BioPharma's binimetinib, an MEK inhibitior.

Companion Diagnostics Market

The following are the major objectives of the study.

  • To define, describe, and forecast the global companion diagnostics market on the basis of product & service, technology, indication, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements & collaborations, and approvals in the global companion diagnostics market

During this research study, Top-down and bottom-up approaches were used to validate the size of the global companion diagnostics market and estimate the size of other dependent submarkets. Various secondary sources such as associations (including Food and Drug Administration (FDA), European Association for Medical Device Reprocessing (EAMDR), Association of Medical Device Reprocessors (AMDR), and Canadian Association of Medical Device Reprocessing (CAMDR)), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

Companion Diagnostics Market

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the global companion diagnostics market are Roche Diagnostics (Switzerland), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), and Abbott Laboratories Inc. (U.S.).

Major Market Developments

  • In 2016, QIAGEN partnered with Mirati Therapeutics, Inc. to develop and commercialize companion diagnostic tests for Mirati’s non-small cell lung cancer therapy glesatinib.
  • In 2016, Roche received FDA approval for its VENTANA ALK (D5F3) to use with XALKORI (crizotinib) drug in patients with ALK-positive lung cancer.
  • In 2016, Agilent Technologies, Inc. and Applied Spectral Imaging (ASI) entered into a marketing agreement. ASI's most advanced GenASIs imaging platforms and Agilent's fluorescence in situ hybridization (FISH) products and solutions will be marketed by them.

Target Audience

  • Pharmaceutical and biotechnology companies
  • Diagnostic manufacturers
  • Research laboratories and academic institutes
  • Research and development (R&D) companies
  • Clinical research organizations (CROs)

Report Scope

Companion Diagnostics Market, by Product & Service

  • Assays & Reagents
  • Software & Services

Companion Diagnostics Market, by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH) 
  • Next-generation Sequencing
  • Other Technologies

*Other technologies include multiplex assay and imaging technology.

Companion Diagnostics Market, by Indication

  • Oncology
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Melanoma 
    • Gastric Cancer 
    • Other Types of Cancer
  • Infectious Diseases
  • Neurology
  • Other Indications

*Other indications include cardiovascular diseases, inflammatory diseases, and inherited diseases

Companion Diagnostics Market, by End User

    • Pharmaceutical and Biopharmaceutical Companies
    • Reference Lab
    • Other End User 

*Other end users include CROs, physician labs, hospital labs, and academic medical centers

Companion Diagnostics Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe (RoE)
  • Asia-Pacific
  • RoW

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Asia-Pacific companion diagnostics market into China, Japan, Australia, and the Rest of APAC

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

The global companion diagnostics market is projected to reach USD 6.51 billion by 2022 from USD 2.61 billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development.

A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain disease could be benefitted by a particular drug through the biomarker assessment. The report analyzes the companion diagnostics market by product & service, technology, indication, end user, and region.

Based on product & service, the assay kits & reagents segment accounted for the largest share in 2016, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH.

The companion diagnostic market in APAC is expected to grow at the highest CAGR during the forecast period. Factors such as the growing need of tailored therapeutics for the elderly population; increasing number of hospitals and diagnostic laboratories; and growing prevalence of life-threatening diseases are driving the growth of the companion diagnostics market in this regional segment.

Companion Diagnostics Market

Rising adoption of companion diagnostics assay kits & reagents in major applications such as oncology, neurology are driving the growth of companion diagnostics market.

Assay Kits and Reagents

Companion diagnostic assay kits include test panels that enable the detection of biomarker types. Companion diagnostics assays analyze the efficacy of a particular drug through the detection of disease biomarker activity against that drug. Companion diagnostic assays are operated on various technology platforms such as polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), and in situ hybridization (ISH). Reagents include components such as staining solutions, acids, bases, buffers, detergents, solutions, and substrates required while performing various companion diagnostic tests. Reagents are products paired to the diagnostic test procedures and have a single-use.

Software and Services

Companion diagnostics software is used to streamline the research and analysis of diagnostic results. Software offers various functions such as the identification of driver vs. passenger mutations, prediction of novel biomarkers, and identification of genes that cause cancer. Companion diagnostic services include the development and commercialization of companion diagnostic (CDx) kits, biomarker assay development, analytical and clinical validation, regulatory registration/approval, cGMP manufacturing, GCP/CLIA certified laboratory, and project management. There are many companies offering end-to-end companion diagnostic services from development to commercialization.

Critical questions the report answers:

  • Where will all these products & services take the industry in the mid to long term?
  • What are the current industry developments for companion diagnostics?

Reimbursement challenges in different regions could limit market growth to a certain extent. Reimbursements for companion diagnostics vary widely across regions and countries. Currently, in most countries, reimbursement is provided only for treatments that offer better clinical results and evidence of performance.

The prominent players in the global companion diagnostics market are Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherland), Illumina Inc. (U.S.). Collaborations and partnerships was the key growth strategy adopted by market players between 2014 and 2017. Companies also aim to differentiate themselves in the highly competitive global companion diagnostics market by expanding their product portfolios in accordance with industry trends and client needs.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered in the Report
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Market Size Estimation
    2.2 Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
                    2.2.2.1 Key Industry Insights
           2.2.3 Assumptions for the Study

3 Executive Summary (Page No. - 26)

4 Premium Insights (Page No. - 30)
    4.1 Global Companion Diagnostics Market Overview
    4.2 Global Market, By Indication
    4.3 Global Market, By Product & Services
    4.4 Global Market, By Technology

5 Market Overview (Page No. - 33)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Improvements in Regulatory Guidelines
                    5.2.1.2 Growing Need for Targeted Therapies
                    5.2.1.3 Rising Cancer Incidence Worldwide
                    5.2.1.4 Increasing Collaborations and Partnerships for Companion Diagnostics Test Development
           5.2.2 Restraints
                    5.2.2.1 Uncertain Reimbursement Scenarios in Different Regions
           5.2.3 Opportunities
                    5.2.3.1 Increasing Demand for Next-Generation Sequencing
                    5.2.3.2 Increasing Number of Clinical Trials to Boost the Adoption of Companion Diagnostics
                    5.2.3.3 Emerging Applications of Companion Diagnostics in Other Cancer Indications, Neurological Disorders, Infectious Diseases, and Cardiovascular Diseases
           5.2.4 Challenge
                    5.2.4.1 Intellectual Property Rights Protection Issues

6 Companion Diagnostics Market, By Product & Service (Page No. - 42)
    6.1 Introduction
    6.2 Assay Kits and Reagents
    6.3 Software & Services

7 Companion Diagnostics Market, By Technology (Page No. - 47)
    7.1 Introduction
    7.2 Polymerase Chain Reaction
    7.3 Immunohistochemistry
    7.4 In Situ Hybridization
    7.5 Next-Generation Sequencing
    7.6 Other Technologies

8 Companion Diagnostics Market, By Indication (Page No. - 59)
    8.1 Introduction
    8.2 Oncology
           8.2.1 Breast Cancer
           8.2.2 Lung Cancer
           8.2.3 Colorectal Cancer
           8.2.4 Melanoma
           8.2.5 Gastric Cancer
           8.2.6 Other Cancers
    8.3 Neurology
    8.4 Infectious Diseases
    8.5 Other Indications

9 Companion Diagnostics Market, By End User (Page No. - 70)
    9.1 Introduction
    9.2 Pharmaceutical and Biopharmaceutical Companies
    9.3 Reference Laboratories
    9.4 Other End Users

10 Companion Diagnostics Market, By Region (Page No. - 77)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 France
             10.3.3 U.K.
             10.3.4 Rest of Europe
     10.4 Asia-Pacific
     10.5 Rest of the World

11 Competitive Landscape (Page No. - 109)
     11.1 Introduction
     11.2 Market Ranking Analysis
     11.3 Competitive Leadership Mapping
             11.3.1 Visionary Leaders
             11.3.2 Innovators
             11.3.3 Dynamic Differentiators
             11.3.4 Emerging Companies
     11.4 Competitive Benchmarking
             11.4.1 Strength of Product Portfolio (For 25 Players)
             11.4.2 Business Strategy Excellence (For 25 Players)

*Top 25 Companies Analyzed for This Studies are - Abbott Laboratories, Inc., Agilent Technologies, Inc., Biomιrieux SA, Danaher Corporation, Illumina Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Diagnostics, Thermo Fisher Scientific, Inc., Arup Laboratories Inc., Sysmex Corporation, Hologic, Inc., Novartis Ag, Almac Group, Abnova Corporation Invivoscribe Technologies, Inc., Foundation Medicine, Inc., Biogenex Laboratories, Inc., Laboratory Corporation of America Holdings, Medical & Biological Laboratories Co., Ltd, Clarity Pharmaceuticals, Researchdx, Inc., Neogenomics Laboratories, Inc., Janssen Diagnostics, Siemens Healthcare Diagnostics Inc.

12 Company Profiles (Page No. - 114)
(Overview, Business Overview, Business Strategy Excellence, Recent Developments)*
     12.1 F. Hoffmann-La Roche AG
     12.2 Agilent Technologies, Inc.
     12.3 Qiagen N.V.
     12.4 Thermo Fisher Scientific Inc.
     12.5 Abbott Laboratories, Inc.
     12.6 Biomιrieux SA
     12.7 Danaher Corporation
     12.8 Illumina, Inc.
     12.9 Myriad Genetics, Inc.
     12.10 Arup Laboratories Inc.
     12.11 Sysmex Corporation
     12.12 Hologic Inc.
     12.13 Novartis AG
     12.14 Almac Group
     12.15 Abnova Corporation

*Details on Marketsandmarkets View, Overview, Overview, Business Overview, Business Strategy Excellence, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 160)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details


List of Tables (105 Tables)

Table 1 Companion Diagnostics Reimbursement Scenario Worldwide
Table 2 Partnerships and Collaborations for Developing Ngs-Based Companion Diagnostic Tests
Table 3 List of Clinical Trials for Companion Diagnostics
Table 4 Global Companion Diagnostics Market, By Product and Service, 2015–2022 (USD Million)
Table 5 Market for Assays & Reagents, By Region, 2015–2022 (USD Million)
Table 6 North America: Market for Assays & Reagents, By Country, 2015–2022 (USD Million)
Table 7 Europe: Market for Assays & Reagents, By Country, 2015–2022 (USD Million)
Table 8 Market for Software & Services, By Region, 2015–2022 (USD Million)
Table 9 North America: Market for Software & Services, By Country, 2015–2022 (USD Million)
Table 10 Europe: Market for Software & Services, By Country, 2015–2022 (USD Million)
Table 11 Global Companion Diagnostics Market, By Technology, 2015–2022 (USD Million)
Table 12 Comparison of Tissue Sequencing Platforms for Detection of Ras/Braf Mutation
Table 13 Companion Diagnostics Market for PCR, By Region, 2015–2022 (USD Million)
Table 14 North America: Market for PCR, By Country, 2015–2022 (USD Million)
Table 15 Europe: Market for PCR, By Country, 2015–2022 (USD Million)
Table 16 Market for Ihc, By Region, 2015–2022 (USD Million)
Table 17 North America: Market for Ihc, By Country, 2015–2022 (USD Million)
Table 18 Europe: Market for Ihc, By Country, 2015–2022 (USD Million)
Table 19 Companion Diagnostics Market for Ish, By Region, 2015–2022 (USD Million)
Table 20 North America: Market for Ish, By Country, 2015–2022 (USD Million)
Table 21 Europe: Market for Ish, By Country, 2015–2022 (USD Million)
Table 22 Companion Diagnostics Market for Ngs, By Region, 2015–2022 (USD Million)
Table 23 North America: Market for Ngs, By Country, 2015–2022 (USD Million)
Table 24 Europe: Market for Ngs, By Country, 2015–2022 (USD Million)
Table 25 Market for Other Technologies, By Region, 2015–2022 (USD Million)
Table 26 North America: Market for Other Technologies, By Country, 2015–2022 (USD Million)
Table 27 Europe: Market for Other Technologies, By Country, 2015–2022 (USD Million)
Table 28 Global Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 29 Market for Oncology, By Type, 2015–2022 (USD Million)
Table 30 Market for Oncology, By Region, 2015–2022 (USD Million)
Table 31 North America: Market for Oncology, By Country, 2015–2022 (USD Million)
Table 32 Europe: Market for Oncology, By Country, 2015–2022 (USD Million)
Table 33 Market for Neurological Disorders, By Region, 2015–2022 (USD Million)
Table 34 North America: Companion Diagnostics Market for Neurological Disorders, By Country, 2015–2022 (USD Million)
Table 35 Europe: Companion Diagnostics Market for Neurological Disorders, By Country, 2015–2022 (USD Million)
Table 36 Companion Diagnostics Market for Infectious Diseases, By Region, 2015–2022 (USD Million)
Table 37 North America: Market for Infectious Diseases, By Country, 2015–2022 (USD Million)
Table 38 Europe: Market for Infectious Diseases, By Country, 2015–2022 (USD Million)
Table 39 Market for Other Indications, By Region, 2015–2022 (USD Million)
Table 40 North America: Market for Other Indications, By Country, 2015–2022 (USD Million)
Table 41 Europe: Market for Other Indications, By Country, 2015–2022 (USD Million)
Table 42 Global Market, By End User, 2015–2022 (USD Million)
Table 43 Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2015–2022 (USD Million)
Table 44 North America: Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015–2022 (USD Million)
Table 45 Europe: Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015–2022 (USD Million)
Table 46 Companion Diagnostics Market for Reference Laboratories, By Region, 2015–2022 (USD Million)
Table 47 North America: Companion Diagnostics Market for Reference Laboratories, By Country, 2015–2022 (USD Million)
Table 48 Europe: Market for Reference Laboratories, By Country, 2015–2022 (USD Million)
Table 49 Market for Other End Users, By Region, 2015–2022 (USD Million)
Table 50 North America: Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 51 Europe: Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 52 Companion Diagnostics Market, By Region, 2015–2022 (USD Million)
Table 53 North America: Companion Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 54 North America: Market, By Product & Service, 2015–2022 (USD Million)
Table 55 North America: Companion Diagnostics Market, By Technology, 2015–2022 (USD Million)
Table 56 North America: Market, By Indication, 2015–2022 (USD Million)
Table 57 North America: Companion Diagnostics Market for Oncology, By Type, 2015–2022 (USD Million)
Table 58 North America: Market, By End User, 2015–2022 (USD Million)
Table 59 U.S.: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 60 U.S.: Market, By Technology, 2015–2022 (USD Million)
Table 61 U.S.: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 62 U.S.: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 63 U.S.: Companion Diagnostics Market, By End User, 2015–2022 (USD Million)
Table 64 Canada: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 65 Canada: Market, By Technology, 2015–2022 (USD Million)
Table 66 Canada: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 67 Canada: Market Size for Oncology, By Type, 2015–2022 (USD Million)
Table 68 Canada: Companion Diagnostics Market, By End User, 2015–2022 (USD Million)
Table 69 Europe: Companion Diagnostics Market, By Country, 2015–2022 (USD Million)
Table 70 Europe: Market, By Product & Service, 2015–2022 (USD Million)
Table 71 Europe: Companion Diagnostics Market, By Technology, 2015–2022 (USD Million)
Table 72 Europe: Market, By Indication, 2015–2022 (USD Million)
Table 73 Europe: Companion Diagnostics Market for Oncology, By Type, 2015–2022 (USD Million)
Table 74 Europe: Market, By End User, 2015–2022 (USD Million)
Table 75 Germany: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 76 Germany: Market, By Technology, 2015–2022 (USD Million)
Table 77 Germany: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 78 Germany: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 79 Germany: Companion Diagnostics Market, By End User, 2015–2022 (USD Million)
Table 80 France: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 81 France: Market, By Technology, 2015–2022 (USD Million)
Table 82 France: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 83 France: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 84 France: Market, By End User, 2015–2022 (USD Million)
Table 85 U.K.: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 86 U.K.: Market, By Technology, 2015–2022 (USD Million)
Table 87 U.K.: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 88 U.K.: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 89 U.K.: Companion Diagnostics Market, By End User, 2015–2022 (USD Million)
Table 90 RoE: Companion Diagnostics Market, By Product & Service, 2015–2022 (USD Million)
Table 91 RoE: Market, By Technology, 2015–2022 (USD Million)
Table 92 RoE: Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 93 RoE: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 94 RoE: Companion Diagnostics Market, By End User, 2015–2022 (USD Million)
Table 95 APAC: Market, By Product & Service, 2015–2022 (USD Million)
Table 96 APAC: Market, By Technology, 2015–2022 (USD Million)
Table 97 APAC: Market, By Indication, 2015–2022 (USD Million)
Table 98 APAC: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 99 APAC: Market, By End User, 2015–2022 (USD Million)
Table 100 RoW: Market, By Product & Service, 2015–2022 (USD Million)
Table 101 RoW: Market, By Technology, 2015–2022 (USD Million)
Table 102 RoW: Market, By Indication, 2015–2022 (USD Million)
Table 103 RoW: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 104 RoW: Market, By End User, 2015–2022 (USD Million)
Table 105 Rank of Companies in the Companion Diagnostics Market, 2016


List of Figures (37 Figures)

Figure 1 Research Design
Figure 2 Bottom Up Approach
Figure 3 Top Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Global Market, By Technology, 2017 vs 2022
Figure 7 Global Market, By Indication, 2017 vs 2022
Figure 8 Global Market, By Products & Services, 2017 vs 2022
Figure 9 Global Market, By End User, 2017 vs 2022
Figure 10 Geographical Snapshot of the Companion Diagnostics Market
Figure 11 Increasing Demand for Targeted Therapy is Boosting the Companion Diagnostics Market
Figure 12 Oncology Segment is Estimated to Account for the Largest Market Share in 2017
Figure 13 Assays & Reagents Segment is Estimated to Account for the Largest Market Share in 2017
Figure 14 Polymerase Chain Reaction is Estimated to Account for the Largest Market Share in 2017
Figure 15 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Increasing Number of New Cancer Cases Worldwide, 2012 vs 2015 vs 2020
Figure 17 Assay Kits and Reagents Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 18 PCR Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 19 Oncology Segment to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 20 Pharmaceutical and Biopharmaceutical Companies Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 21 Geographic Snapshot: Asia-Pacific Market to Register Highest Growth During the Forecast Period
Figure 22 North American Companion Diagnostics Market Snapshot
Figure 23 European Companion Diagnostics Market Snapshot
Figure 24 Asia-Pacific Companion Diagnostics Market Snapshot
Figure 25 Competitive Leadership Mapping, 2017
Figure 26 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 27 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 28 Qiagen N.V.: Company Snapshot (2016)
Figure 29 Thermo Fisher Scientific Inc.: Company Snapshot (2016)
Figure 30 Abbott Laboratories, Inc.: Company Snapshot (2016)
Figure 31 Biomιrieux SA: Company Snapshot (2016)
Figure 32 Danaher Corporation: Company Snapshot (2016)
Figure 33 Illumina, Inc.: Company Snapshot (2016)
Figure 34 Myriad Genetics, Inc.: Company Snapshot (2016)
Figure 35 Sysmex Corporation: Company Snapshot (2016)
Figure 36 Hologic, Inc.: Company Snapshot (2016)
Figure 37 Novartis AG: Company Snapshot (2016)


Request for detailed methodology, assumptions & how numbers were triangulated.

Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
MD 5463
Published ON
Aug, 2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved